213 related articles for article (PubMed ID: 31708515)
1. Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan.
Masaki Y; Kawabata H; Fujimoto S; Kawano M; Iwaki N; Kotani T; Nakashima A; Kurose N; Takai K; Suzuki R; Aoki S
J Clin Exp Hematop; 2019 Dec; 59(4):175-178. PubMed ID: 31708515
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of Castleman Disease.
Simpson D
Hematol Oncol Clin North Am; 2018 Feb; 32(1):1-10. PubMed ID: 29157611
[TBL] [Abstract][Full Text] [Related]
3. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
[TBL] [Abstract][Full Text] [Related]
4. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y
Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.
Nagy A; Bhaduri A; Shahmarvand N; Shahryari J; Zehnder JL; Warnke RA; Mughal T; Ali S; Ohgami RS
Blood Adv; 2018 Mar; 2(5):481-491. PubMed ID: 29496669
[TBL] [Abstract][Full Text] [Related]
6. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.
Zhou QY
World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591
[TBL] [Abstract][Full Text] [Related]
7. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S
Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500
[TBL] [Abstract][Full Text] [Related]
8. Historical and pathological overview of Castleman disease.
Nishimura MF; Nishimura Y; Nishikori A; Yoshino T; Sato Y
J Clin Exp Hematop; 2022 Jun; 62(2):60-72. PubMed ID: 35474035
[TBL] [Abstract][Full Text] [Related]
9. Use of a claims database to characterize and estimate the incidence rate for Castleman disease.
Munshi N; Mehra M; van de Velde H; Desai A; Potluri R; Vermeulen J
Leuk Lymphoma; 2015 May; 56(5):1252-60. PubMed ID: 25120049
[TBL] [Abstract][Full Text] [Related]
10. TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?
Takai K
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540266
[TBL] [Abstract][Full Text] [Related]
11. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase 3β/CCR6-positive bone marrow cells correlate with disease activity in multicentric Castleman disease-TAFRO.
Abe N; Kono M; Kono M; Ohnishi N; Sato T; Tarumi M; Yoshimura M; Sato T; Karino K; Shimizu Y; Fujieda Y; Kato M; Hasebe R; Oku K; Murakami M; Atsumi T
Br J Haematol; 2022 Mar; 196(5):1194-1204. PubMed ID: 34873687
[TBL] [Abstract][Full Text] [Related]
13. Unicentric Castleman disease: A case report of an atypical presentation and successful management.
Muhammad T; Alkheder A; Mazloum A; Almooay A; Naziha L; Shaheen M
Int J Surg Case Rep; 2024 May; 118():109688. PubMed ID: 38669805
[TBL] [Abstract][Full Text] [Related]
14. Castleman disease and TAFRO syndrome.
Masaki Y; Arita K; Sakai T; Takai K; Aoki S; Kawabata H
Ann Hematol; 2022 Mar; 101(3):485-490. PubMed ID: 35044513
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review.
Fayand A; Boutboul D; Galicier L; Kahn JE; Buob D; Boffa JJ; Cez A; Oksenhendler E; Grateau G; Ducharme-Bénard S; Georgin-Lavialle S
Amyloid; 2019 Dec; 26(4):197-202. PubMed ID: 31364863
[No Abstract] [Full Text] [Related]
16. Borderline Case of TAFRO Syndrome and POEMS Syndrome.
Shibata S; Tabata S; Morita H; Endo T; Kawasaki N; Okamoto Y; Inano S; Takiuchi Y; Fukunaga A; Kitano T
Intern Med; 2021 May; 60(10):1589-1595. PubMed ID: 33328401
[TBL] [Abstract][Full Text] [Related]
17. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
Okamoto S
Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
[TBL] [Abstract][Full Text] [Related]
18. The French paediatric cohort of Castleman disease: a retrospective report of 23 patients.
Borocco C; Ballot-Schmit C; Ackermann O; Aladjidi N; Delaleu J; Giacobbi-Milet V; Jannier S; Jeziorski E; Maurier F; Perel Y; Piguet C; Oksenhendler E; Koné-Paut I; Galeotti C
Orphanet J Rare Dis; 2020 Apr; 15(1):95. PubMed ID: 32303241
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of Castleman disease.
Soumerai JD; Sohani AR; Abramson JS
Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
[TBL] [Abstract][Full Text] [Related]
20. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study.
Sopfe J; Endres A; Campbell K; Hayes K; Trout AT; Liang X; Lorsbach R; O'Brien MM; Cost CR
Pediatr Blood Cancer; 2019 May; 66(5):e27613. PubMed ID: 30680887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
